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ABSTRACT
Background Due to rising numbers of STI diagnosis 
and increasing prevalence of antimicrobial resistance, 
we explored trends in STI testing frequency and 
diagnoses, alongside sexual decision making and 
attitudes concerning condom use and HIV pre- exposure 
prophylaxis (PrEP) at a large urban UK sexual health 
clinic.
Methods We examined 66 528 electronic patient 
records covering 40 321 attendees between 2016 and 
2019, 3977 of whom were men who have sex with men 
or trans persons who have sex with men (MSM/TPSM). 
We also explored responses from MSM/TPSM attendees 
sent an electronic questionnaire between November 
2018 and 2019 (n=1975) examining behaviours/
attitudes towards PrEP. We measured trends in STI 
diagnoses and sexual behaviours including condomless 
anal intercourse (CAI), using linear and logistic 
regression analyses.
Results Tests resulting in gonorrhoea, chlamydia or 
syphilis diagnoses increased among MSM/TPSM from 
13.5% to 18.5% between 2016 and 2019 (p<0.001). 
The average MSM/TPSM STI testing frequency increased 
from 1.5/person/year to 2.1/person/year (p=0.017). Gay 
MSM/TPSM had the highest proportions of attendances 
resulting in diagnoses, increasing from 15.1% to 19.6% 
between 2016 and 2019 (p<0.001) compared with 
bisexual/other MSM/TPSM increasing from 6.9% to 
14.5% (p<0.001), alongside smaller but significant 
increases in non- MSM/TPSM from 5.9% to 7.7% 
(p<0.001).
The proportion of MSM/TPSM clinic attendees reporting 
CAI in the previous 3 months prior to at least one 
appointment in a given year increased significantly from 
40.6% to 45.5% between 2016 and 2019 (p<0.0001) 
and average number of partners from 3.8 to 4.5 
(p=0.002). Of 617 eligible questionnaire responses, 
339/578 (58.7%) HIV- negative and 29/39 (74.4%) HIV- 
positive MSM/TPSM indicated they would be more likely 
to have CAI with someone on PrEP versus not on PrEP. 
358/578 (61.9%) HIV- negative respondents said that 
PrEP use would make them more likely to have CAI with 
HIV- negative partners.
Conclusion Rising numbers of STI diagnoses among 
MSM/TPSM are not attributable to increased testing 
alone. Increased CAI and number of partners may be 
attributable to evolving sexual decision making among 
PrEP users and their partners. Proportionally, bisexual/
other MSM/TPSM have the steepest increase in STI 
diagnoses.
INTRODUCTION
In England, STIs diagnoses continue to increase 
with 450 000 reported in 2018, a 5% rise since 
2017.1 Proportionally, rates of diagnosis of syph-
ilis (Treponema pallidum (TP)), gonorrhoea (Neis-
seria gonorrhoeae (GC)) and chlamydia (Chlamydia 
trachomatis (CT)) are higher in gay, bisexual 
and other men who have sex with men (MSM) 
compared with heterosexual cisgender men and 
women and are highest among HIV- diagnosed 
MSM.1 Gonorrhoea cases increased the most (26% 
rise) with 47% of cases in MSM. Between 2009 
and 2018, gonorrhoea increased 6.4- fold among 
MSM,1 which is especially concerning given rising 
antimicrobial resistance (AMR).2–4
The reasons for increased diagnoses of STIs in 
MSM are complex.1 5 These may include improved 
detection of STIs through increased testing, for 
example, more extra- genital testing in asympto-
matic patients or usage of home/postal testing. 
Conversely, behavioural changes could increase STI 
transmission: increases in sexual partner numbers; 
condomless anal intercourse (CAI); group sex; and 
sexualised use of illicit substances to enhance or 
prolong sexual intercourse (chemsex) facilitated 
by geosocial networking applications.6 With more 
widespread knowledge of U=U and availability of 
pre- exposure prophylaxis (PrEP), decisions to move 
away from condom use as the primary prevention 
strategy among both people living with and without 
HIV alike may enable significant increases in bacte-
rial STIs.
Since 2015, HIV incidence has declined due to 
increased HIV testing, treatment as prevention and 
increasing availability of HIV PrEP, an antiretroviral 
medication taken before and during periods of HIV 
risk, with high efficacy for preventing HIV acquisi-
tion.7–9 PrEP is currently available through National 
Health Service (NHS) sexual health services in Wales 
and Scotland10 and will be rolled out in England 
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during 2020.11 Previously, PrEP has had limited availability in 
England, with free NHS access restricted to those enrolled on 
the Impact trial.12 In MSM and trans persons who have sex with 
men (TPSM), eligibility for the trial primarily involves reporting 
ongoing CAI or other factors posing similar HIV risk.12
There have been concerns that PrEP use could result in 
increased sexual risk- taking behaviours among HIV- negative 
MSM further increasing the incidence of STIs.7 Recent studies 
have given a consistent picture that the incidence of STIs in 
MSM increases following initiation of PrEP, but it is unclear 
whether this primarily reflects increased STI testing.13 14
We investigate factors contributing to rising STI incidence 
in MSM/TPSM by examining the trends from January 2016 
to December 2019 in STI diagnoses, testing and sexual behav-
iours alongside attitudes towards PrEP use among MSM/TPSM 
attending a large non- London urban sexual health centre.
METHODS
Population and setting
This work is part of the Challenges and Opportunities of PrEP 
(CHOP) Study, a mixed methods study combining analysis of: 
(1) routinely collected clinic data, January 2016–December 
2019; (2) a self- completed online questionnaire carried out from 
31 October 2018 to 31 October 2019 and (3) qualitative inter-
views with selected participants from (2). The study population 
are attendees of a large urban sexual health centre in Bristol, UK, 
which does not manage HIV- positive patients. For this paper, we 
consider clinic and online questionnaire data only; the qualita-
tive interview data will be published elsewhere.15
Electronic patient records (EPRs)
At each clinic visit, an EPR is completed, which contains all clin-
ical information recorded during the consultation, tests under-
taken and results. Each attendance is coded using the enhanced 
Genitourinary Medicine Clinical Activity Dataset (GUMCADv3), 
which has been used in Bristol since 2015. GUMCADv3 includes 
extended information on sexual behaviour including CAI, 
number of partners and recreational drug use, not recorded in 
GUMCADv2.16
We included all EPRs with a recorded STI test in our study 
period. Classification as MSM/TPSM was through self- 
identification as male gender (cis or transgender), with sexual 
orientation coded through the EPR as those who only have sex 
with men (gay) and those who have sex with men, women and/
or other genders (bisexual/other). All attendees not meeting 
these criteria were classified as non- MSM/TPSM; this category 
included trans female attendees, due to the inability to reliably 
differentiate cis female and trans female attendees from the EPR 
dataset.
Questionnaire
An electronic questionnaire was developed using Research Elec-
tronic Data Capture, including questions on sociodemographic 
characteristics, sexual health service use, sexual behaviour in 
previous 3 months, and views and experiences of PrEP. The elec-
tronic questionnaire link was distributed via SMS to all MSM/
TPSM clinic attendees who consented to text communication 
with valid UK mobile numbers, for 12 months from 31 October 
2018.
The inclusion criteria were: (1) consent to participate in the 
study; (2) indication that the respondent self- identified as MSM/
TPSM (inclusive of both trans male and trans female respond-
ents); and (3) complete answers on questions concerning 
condom use; HIV status (including ‘unsure’) and opinions and 
attitudes towards PrEP.
Analysis
We describe the demographics of clinic attendees (EPR dataset) 
and questionnaire respondents, to ascertain representativeness 
of survey respondents. We compared age, ethnicity and index 
of multiple deprivation score categories using goodness of fit χ2 
testing.
Using the clinical EPR data, we then examined the trends in 
STI diagnoses using linear regression, performing this analysis 
among both non- MSM/TPSM and MSM/TPSM attendees. We 
also evaluated trends in any CAI, number of partners and partic-
ipation of chemsex (defined as use of crystal meth, mephedrone 
and/or GHB) in the 3 months prior to attendances alongside 
the proportion of attendances resulting in use of postexpo-
sure prophylaxis, following possible sexual exposure to HIV 
(PEPSE). For the purposes of this analysis, we define the number 
of ‘unique testers’ in a given year to be the number of individual 
MSM/TPSM attending for testing. We also define MSM/TPSM 
having only ever visited the clinic once for testing as ‘one- off 
testers’ and those having at least two STI tests within the clinic 
(at any time- point) as ‘repeat- testers’.
Finally, we examine CHOP questionnaire responses using 
univariate binary logistic regression models to calculate the 
crude ORs for the presence/absence of risk factors associated 
with STI acquisition. We define an independent categorial vari-
able of: (1) PrEP users; (2) HIV negative or HIV status unsure 
(HIV negative/unsure) non- PrEP users; and (3) HIV- diagnosed 
MSM. Responses including missing data for variables of interest 
were excluded from the analysis.
We then describe questionnaire responses exploring how atti-
tudes towards PrEP may influence changes in CAI. Specifically, 
we used an agreement scale (strongly disagree, disagree, not sure/
don’t know, agree and strongly agree) in conjunction with the 
following statements: (1) ‘I would be more likely to have anal 
sex without a condom with someone I believe is HIV- negative 
if I was on PrEP’; (2) ‘I would be more likely to have anal sex 
without a condom with someone I believe is HIV- positive if 
I was on PrEP’; and (3) ‘I would be more likely to have anal 
sex without a condom with someone who was on PrEP than 
someone who was not on PrEP’.
All analyses were performed in STATA V.15.
RESULTS
Demographics
Clinic records EPRs for 2016–2019 included 66 528 attendances 
(40 321 attendees) in which STI testing was undertaken. Of these, 
10 794 attendance records (3977 attendees) were MSM/TPSM. 
Further breakdowns are provided in online supplemental figure 
S1. MSM/TPSM were primarily white 3429/3848 (90.7%), had 
sex with men only 3055/3975 (76.9%) and just over half were 
under 30 years 108/3975 (53.0%). Questionnaire invitations 
were sent to 1975 MSM/TPSM between 1 October 2018 and 1 
October 2019, with 617 (31.2%) responses eligible for analysis. 
Questionnaire respondents were older, more ethnically diverse, 
but with similar indices of multiple deprivation compared with 
the clinical cohort (table 1).
Testing trends
Clinical EPR data among MSM/TPSM indicated that the number 
of attendances at which an STI test was carried out increased 
from 2286 (2016) to 3039 (2019), an increase of 245 attendances 
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per year (p=0.008) (figure 1). However, the number of unique 
testers (each year) remained stable (p=0.394), from 1545 to 
1693. Regarding repeat- testers, tests taken per year increased on 
average from 1.5 to 2.1 (p=0.017).
The clinical EPR data also indicated that among TPSM/
MSM, the total number of bacterial STIs (CT/GC/TP) diagnosed 
increased from 309 in 2016 to 565 in 2019 and the proportion 
of attendances resulting in a bacterial STI diagnosis increased 
from 13.5% to 18.5% (p<0.001), with an annual increase of 94 
Table 1 Demographics of MSM/TPSM questionnaire participants and MSM/TPSM clinic attendees
Demographics
Number of questionnaire 
respondents %




Age (years) 617 3975 4592 (3)
  <30 198 32.1 2108 53.0 112.3
  30–49 293 47.5 1467 36.9 <0.0001
  >50 126 20.4 400 10.1   
Ethnicity 617 3848 4465 (7)
  White British 413 66.9 2906 75.5 37.7
  White other 114 18.5 586 15.2 <0.0001
  Mixed/multiple ethnic groups 29 4.7 89 2.3   
  Asian/Asian British 34 5.5 142 3.7   
  Black/African/Caribbean/black British 13 2.1 26 0.7   
  Prefer not to say 9 1.5 71 1.8   
  Other 5 0.8 28 0.7   
Highest qualification 616 – –
  No educational qualifications 10 1.6 – – –
  GCSEs or equivalent 62 10.1 – – –
  A- levels or equivalent 81 13.1 – –   
  BTEC/NVQ/diploma or equivalent 80 13.0 – –   
  University degree or higher 378 61.4 – –   
  Other 5 0.8 – –   
Index of multiple deprivation (IMD)‡ 398 3759 4157 (5)
  Quintile 1 (most deprived) 64 16.1 708 18.8 6.8
  Quintile 2 89 22.4 860 22.9 0.1480
  Quintile 3 99 24.9 751 20.0   
  Quintile 4 72 18.1 767 20.4   
  Quintile 5 (least deprived) 74 18.6 673 17.9   
Sexuality 617 3975 –
  Sex with men 499 80.9 3055 76.9 –
  Sex with men and women 64 10.4 918 23.1 –
  Other sexual preference 54 8.8 2 0.1   
Gender 617 – –
  Cis male 599 97.1 – – –
  Transgender 5 0.8 – – –
  Non- binary/other 13 2.1 – –   
HIV status 617 – –
  Unaware of their HIV status 26 4.2 – – –
  HIV positive 39 6.3 – – –
  HIV negative 552 89.5 – –   
PrEP use (in HIV- negative MSM/TPSM) 578 – – –
  PrEP eligible (total) 402 69.6 – – –
  Has never used PrEP and is ineligible 155 26.8 – – –
  Has never used PrEP but is eligible 221 38.2 – –   
  Is currently using PrEP and is ineligible 12 2.1 – –   
  Is currently using PrEP and is eligible 162 28.0 – –   
  Has previously used PrEP and is ineligible 9 1.6 – –   
  Has previously used PrEP and is eligible 19 3.3 – –   
*Multiple visits may be associated with each clinic identification number; we use demographic information relating to the most recent visit between 1 December 2016 and 30 
November 2019. Education, gender assigned at birth, PrEP use and HIV status could not be reliably discerned from clinical attendance records.
†χ2 test of goodness of fit, expressed with df and p value.
‡IMD is an overall measure of the relative deprivation based on geographical area of residence (specifically lower layer super output area).
BTEC, Business and Technology Education Council; GCSE, General Certficate of Secondary Education; MSM, men who have sex with men; NVQ, National Vocational Qualification; 
PrEP, pre- exposure prophylaxis; TPSM, trans persons who have sex with men .
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infections per year (p=0.035). At least one of CT/GC/TP were 
diagnosed in 18.6% of individual attendees in 2016 compared 
with 27.4% in 2019 (3.4% increase per year; p<0.001). Gay 
MSM/TPSM had the highest proportions of attendances 
resulting in CT/GC/TP diagnoses in any given year (from 15.1% 
to 19.6%; p<0.001) compared with bisexual/other MSM/
TPSM (6.9% to 14.5%; p<0.001), although the largest relative 
increase in the proportion of attendances resulting in diagnosis 
with CT/GC/TP was among bisexual/other MSM (figure 2). 
Similar trends were observed among non- MSM/TPSM clinic 
attendees; however, the proportion of attendances resulting in 
diagnoses were consistently lower than MSM/TPSM, increasing 
from 5.9% to 7.7% (p<0.001).
Behavioural trends
The EPR data indicate that among MSM/TPSM, the proportion 
reporting CAI in the past 3 months during at least one appoint-
ment per calendar year rose from 40.6% to 45.5% between 
2016 and 2019 (p<0.001), among repeat- testers increasing 
from 40.0% to 46.4% (p<0.001) but with no statistically signif-
icant change among one- off testers (p=0.065). The number of 
MSM/TPSM attendees who would be eligible for PrEP based on 
reported CAI increased from 627 to 771 (online supplemental 
figure S2), some of whom may already be using PrEP.
For MSM/TPSM attendees, the average number of part-
ners reported (in the 3 months prior to the appointment) in 
all appointments in a calendar year increased from 3.8 to 4.5 
(p=0.002), among repeat- testers increasing from 3.8 to 5.2 
(p=0.001), again with no statistically significant change among 
one- off testers.
The proportion of MSM/TPSM attendees who had partic-
ipated in chemsex in the past 3 months during at least one 
appointment in each calendar year rose from 2.1% to 3.3% 
(p=0.024), while the proportion prescribed PEPSE rose from 
3.5% to 4.6% (p=0.033). The trends among repeat- testers 
and one- off testers for these behaviours were not significant; 
however, due to the rarity of these outcomes and the stratifica-
tion of our population into subgroups, our analysis is likely to be 
underpowered in detecting these trends.
Behaviours and attitudes towards PrEP
Among questionnaire respondents (of whom all were MSM/
TPSM), 39/617 (6.3%) stated they were HIV- positive and 
578/617 (93.7%) stated they were HIV negative/unsure, of 
which 174 (30.1%) were currently using PrEP. A total of 432 of 
617 (70.0%) of respondents had engaged in CAI in the past 3 
months. Furthermore, 42/615 (6.8%) had engaged in chemsex; 
53/579 (9.2%) been prescribed PEPSE; and 42/582 (7.2%) had 
Figure 1 (A) Number of total MSM/TPSM attendances in which 
bacterial STI testing was undertaken between 2016 and 2019 and 
number of individuals attending clinic who had at least one bacterial STI 
test in a given year alongside the total number of associated diagnoses 
with STIs from these attendances or number of individuals attending 
clinic with at least one diagnosis of a bacterial STI in any given year. 
(B) Trends in chlamydia, gonorrhoea and syphilis diagnoses in MSM/
TPSM among attendances in which bacterial STI testing was undertaken 
between 2016 and 2019, along with associated lines of best fit, using 
GUMCADv3 data from clinical attendances. MSM, men who have sex 
with men; TPSM, trans persons who have sex with men.
Figure 2 Trends in chlamydia, gonorrhoea and syphilis in (A) 
homosexual MSM/TPSM, (B) bisexual/other MSM/TPSM and (C) all other 
clinic attendees between 2016 and 2019, along with associated lines 
of best fit, using GUMCADv3 data from clinical attendances. MSM, men 
who have sex with men; TPSM, trans persons who have sex with men.
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had rectal CT/GC or acute TP in the past 12 months, with break-
downs by HIV- status and PrEP use included in table 2.
The questionnaire data indicated that, compared with HIV- 
negative/unsure respondents not using PrEP, PrEP users were 
more likely to have had CAI in the past 3 months (OR 9.2 (95% 
CI 5.0 to 17.1, p<0.001)), participated in chemsex (OR 7.7 
(95% CI 3.5 to 16.9, p<0.001)), been prescribed PEPSE (OR 
2.3 (95% CI 1.3 to 4.0, p=0.005)) or been diagnosed with rectal 
CT/GC and/or acute TP (OR 2.1 (95% CI 1.1 to 4.1, p=0.035)) 
in the past 12 months.
Furthermore, a total of 339/578 (58.7%) HIV- negative/unsure 
questionnaire respondents and 29/39 (74.4%) of HIV- positive 
respondents stated that they would be more likely to have CAI 
with someone who was on PrEP than someone who was not 
on PrEP. While 358/578 (61.9%) and 162/578 (28.0%) of HIV- 
negative/unsure respondents said that if they were using PrEP, 
they would be more likely to have CAI with someone who they 
believed were HIV- negative/positive, respectively (online supple-
mental figure S3).
DISCUSSION
The number of attendances by MSM/TPSM for STI/HIV testing 
has increased by approximately 10% per annum between 2016 
and 2019. This is as a result of more frequent testing per individual 
rather than an increase in unique MSM/TPSM attending the 
clinic. The total number of bacterial STIs (GC, CT and TP) diag-
nosed in MSM/TPSM also significantly increased, most notably 
in bisexual/other MSM/TPSM compared with gay MSM/TPSM. 
While bacterial STI diagnoses were less common for non- MSM/
TPSM attendances, we also observed a significantly increasing 
trend. Behaviours associated with STI risk also increased among 
MSM/TPSM. With repeat- testers having the largest increases in 
frequency of CAI and average number of partners, potentially 
suggesting that health promotion messages regarding regular 
testing when at increased STI risk are working.
We find some evidence that rising incidence of bacterial STI 
diagnoses is due to an increase in partner numbers, CAI and 
chemsex drug use. Importantly, among survey respondents, PrEP 
users were more likely to report CAI and other risk factors for HIV 
and bacterial STI acquisition than HIV- negative/unsure MSM/
TPSM not using PrEP. Interestingly, even among HIV- negative/
unsure MSM, a potential partner using PrEP was frequently indi-
cated to result in a higher chance of CAI, furthering evidence 
that community- wide increases in CAI could be driven by PrEP. 
This observation resonates worldwide, with rapid rises in PrEP 
uptake in Australia followed by rapid increases in CAI,17 CAI 
increasing in frequency among PrEP users in the Netherlands18 
and rising PrEP uptake occurring alongside an increasing rate of 
CAI in the USA.19 Importantly, however, an increase in CAI was 
not an unexpected or even necessarily a negative consequence of 
PrEP.20 Given PrEP as an additional tool, MSM/TPSM are likely 
to consider and re- evaluate their own HIV risk management 
strategies21 22 against competing interests such as maximising 
sexual pleasure and feeling connected to their partners.23
The challenge however is to balance HIV risk and sexual 
pleasure, with the competing risks of STIs and the emergence 
and spread of AMR, particularly extensively drug- resistant GC, 
notably seen in the strains reported in recent UK case studies.2–4 24
A recent Australian study identified bisexual individuals as a 
possible bridging population between GC transmission clusters 
Table 2 Associations between HIV risk factors and CHOP questionnaire respondent’s HIV status and current PrEP usage
Risk behaviours for HIV and demographic 
categories Respondents in subgroup (%) Number with risk factor (%) OR* (95%CI) P value
CAI in the past 3 months



















Diagnosis with a rectal gonorrhoea, chlamydia or acute syphilis in the past 12 months



















PEP use in the past 12 months
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CHOP, Challenges and Opportunities of PrEP; PEP, post- exposure prophylaxis; PrEP, pre- exposure prophylaxis.
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in MSM and heterosexual populations.25 This is of concern due 
to increasing bacterial STI diagnoses in both the MSM/TPSM 
and non- MSM/TPSM subpopulations, which are likely to be 
linked via mechanisms such as ‘bisexual bridging’. However, the 
direction and magnitude of this effect in our clinic population 
remains unknown and is beyond the scope of this study.
Another study defined the ‘PrEP- gap’ as the difference 
between MSM/TPSM currently using PrEP and MSM/TPSM 
who would be ‘very likely’ to use PrEP if they could access it.26 
In the UK, PrEP use could triple from current rates to nearly 
30% of the MSM/TPSM population. Given our findings and the 
current roll- out of PrEP across England,11 this could have signif-
icant consequences for condom use, continued increases in STI 
incidence and AMR.
The UK is not alone in experiencing rising rates of bacterial 
STI diagnoses, with rising trends being reported internation-
ally.27 28 Understanding the influence of behavioural changes 
and the role of PrEP as an emergent part of HIV combination 
prevention is vital, with many countries committed to reducing 
the number of new HIV diagnoses and reaching the UNAIDS 
90:90:90 targets.
The full interplay of increased testing, increasing PrEP use and 
the behavioural factors we have discussed such as CAI, increased 
sexual partner numbers and chemsex is difficult to determine 
and would benefit from further investigation, potentially using 
mathematical modelling. However, what is clear is that to tackle 
the issue of rising STI rates in the evolving landscape of PrEP, we 
must consider a holistic approach that addresses multiple factors, 
including facilitating MSM/TPSM to make informed decisions 
about the risks of CAI beyond HIV prevention strategies. We 
now face the challenge of addressing sexual health messaging in 
an era of reduced HIV anxiety and fear.29
Strengths and limitations
This study brings recent and extensive data from a large urban 
setting outside London. Bristol is a Fast Track City30 committed 
to the elimination of new HIV diagnoses by 2030.9 Under-
standing the attitudes, STI trends and needs of cities outside of 
London remain a key endeavour to reach this target in the whole 
of the UK.
This study benefits from high data quality, resulting from use 
of the EPR mandatory fields (made uniquely possible in Bristol 
as a legacy of the GUMCAD3 pilot). We also used two comple-
mentary data sets, including a more detailed behavioural ques-
tionnaire to provide evidence to suggest how attitudes towards 
PrEP usage may lead to rising trends in CAI. Finally, this work 
takes a balanced approach in holistically examining multiple 
factors to explore the reasons for a continuing rise in common 
STI diagnoses in MSM/TPSM in the UK.
Due to convenience sampling and the subject material, the 
questionnaire respondents may be more likely to have an interest 
in PrEP or HIV prevention.31 Findings may not be generalisable 
to UK MSM/TPSM attending non- urban settings. Behavioural 
variables were self- reported and vulnerable to recall and social 
desirability bias. EPRs are clinician completed within the attend-
ance and then updated to include processed results separately, 
potentially leading to missing information. Informal PrEP usage 
among clinic attendees was not available through GUMCAD 
coding, and knowledge of PrEP status was limited to responses 
given in the questionnaire. Furthermore, the EPR data did not 
include detailed information around gender identity, which 
meant we could not reliably determine all transgender attendees 
(in particular transgendered attendees identifying as female). 
This will be possible now that a revised GUMCADv3 has been 
implemented in all UK GUM clinics. The low number of trans-
gender participants also meant that subpopulation analysis was 
not feasible. Lastly, from the EPRs, data were not possible to 
establish whether use of chemsex- related substances was solely 
during sexual intercourse.
In addition, the introduction of an online postal testing system 
in June 2017 may have affected in- clinic testing but is not link 
to other clinical attendee EPR records. The study clinic also 
introduced a rapid STI service for all symptomatic attendees in 
November 2018 with results of CT/GC available within 2 days. 
We however expect the impact of this new service on attend-
ance patterns to be small, as this service was not advertised 
externally of the clinic and was only offered to attendees who 
were symptomatic and thus would have been likely to attend 
the service regardless of clinical pathway. Finally, people living 
with HIV were also likely to be testing for STIs at specialised 
services outside of the study clinic, and hence our sample of 
HIV- diagnosed MSM may not be largely representative of all 
HIV- diagnosed MSM.
CONCLUSION
MSM/TPSM STI diagnosis rates are increasing, and higher 
testing frequency is a likely contributor, alongside changes in 
sexual behaviours and decision making. The highest propor-
tion of visits resulting in STI diagnoses is among gay MSM/
TPSM (19.6% in 2019), but the largest increase (6.9%–14.9%, 
2016–2019) is among bisexual MSM/TPSM, which could lead 
to higher rates of STIs and AMR and thus increased morbidity 
and adverse health outcomes in other groups through bisexual 
bridging.
CAI and other risk behaviours are being reported more 
frequently across MSM/TPSM clinic attendees, especially among 
repeat- testers. MSM/TPSM taking PrEP, along with their part-
ners (whether HIV negative or HIV positive), are more likely to 
have CAI compared with when neither partner is on PrEP.
Opportunities for public health and risk- reduction messaging 
for MSM/TPSM should be optimised for regular attendees. 
For example among PrEP users, to encourage informed deci-
sion making around CAI, which extends beyond anticipated 
increased risk of STIs to also include information regarding 
AMR and the potential of untreatable diseases. Public health 
understanding and awareness is likely to be facilitated by mass 
public experiential learning and education about infectious 
disease morbidity, transmission, spread and control measures as 
a result of the SARS- CoV-2 pandemic. Given the evidence of 
potential spread to non- MSM/TPSM populations and associated 
morbidity, MSM/TPSM should not be considered in isolation in 
terms of promoting regular testing, robust partner notification 
and sexual health promotion.
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